Reply

Abstract

In the current study, using the risk stratification provided by the current guideline, we have demonstrated that even in the low-risk group, the recurrence rate beyond the 5-year tumor-free period was the same as those in the intermediate and high-risk groups. We would like to emphasize that long-term follow-up data could provide the true prognostic factors for tumor recurrence and/or progression in patients with non-muscle–invasive bladder cancer and would answer the question as to whether the current management protocol could improve the treatment outcome. Especially for the high-risk group, current management such as second TUR-BT and/or maintenance BCG therapy should also be evaluated in terms of their benefits in this longer follow-up setting. Surgery-related Complications in 1253 Robot-assisted and 485 Open Retropubic Radical Prostatectomies at the Karolinska University Hospital, SwedenUrologyVol. 75Issue 5PreviewTo quantify complications to surgery in patients treated with robot-assisted radical prostatectomy (RARP) and open retropubic radical prostatectomy (RRP) at our institution. Radical prostatectomy is associated with specific complications that can affect outcome results in patients. Full-Text PDF Editorial CommentUrologyVol. 75Issue 6PreviewThe urologic literature is rich in retrospective studies of clinical outcomes for noninvasive bladder cancer treated with TUR-BT (either alone or with adjuvant intravesical therapy) with short- and intermediate-term results. Based on these studies, a need to better categorize patients with TaT1 tumors arose, and patients were divided into risk groups (low-risk, intermediate-risk, and high risk) based on prognostic factors derived from multivariate analyses. When using these risk groups, however, no difference is usually made between the risk of recurrence and progression. Full-Text PDF